MA55815A - Traitement de céphalées à l'aide d'anticorps anti-cgrp - Google Patents

Traitement de céphalées à l'aide d'anticorps anti-cgrp

Info

Publication number
MA55815A
MA55815A MA055815A MA55815A MA55815A MA 55815 A MA55815 A MA 55815A MA 055815 A MA055815 A MA 055815A MA 55815 A MA55815 A MA 55815A MA 55815 A MA55815 A MA 55815A
Authority
MA
Morocco
Prior art keywords
headaches
treatment
cgrp antibodies
cgrp
antibodies
Prior art date
Application number
MA055815A
Other languages
English (en)
French (fr)
Inventor
Roger K Cady
Joseph Hirman
Lahar Mehta
Barbara Schaeffler
Jeffrey T L Smith
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/012781 external-priority patent/WO2020146527A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA55815A publication Critical patent/MA55815A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA055815A 2019-05-02 2020-02-18 Traitement de céphalées à l'aide d'anticorps anti-cgrp MA55815A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842162P 2019-05-02 2019-05-02
US201962872989P 2019-07-11 2019-07-11
PCT/US2020/012781 WO2020146527A1 (en) 2019-01-08 2020-01-08 Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Publications (1)

Publication Number Publication Date
MA55815A true MA55815A (fr) 2022-03-09

Family

ID=73028680

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055815A MA55815A (fr) 2019-05-02 2020-02-18 Traitement de céphalées à l'aide d'anticorps anti-cgrp

Country Status (20)

Country Link
US (1) US20220251178A1 (https=)
EP (1) EP3962522A4 (https=)
JP (2) JP2022533030A (https=)
KR (1) KR20220004053A (https=)
CN (1) CN113811326A (https=)
AU (1) AU2020267107B2 (https=)
BR (1) BR112020027063A2 (https=)
CA (1) CA3133571A1 (https=)
CL (1) CL2021002866A1 (https=)
DO (1) DOP2021000215A (https=)
EA (1) EA202192865A1 (https=)
GE (2) GEP20257803B (https=)
IL (1) IL287759A (https=)
JO (1) JOP20210247A1 (https=)
MA (1) MA55815A (https=)
MX (1) MX2021013426A (https=)
PH (1) PH12021552422A1 (https=)
SG (1) SG11202110637RA (https=)
WO (1) WO2020222892A1 (https=)
ZA (1) ZA202106627B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310885A (en) * 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
KR20240058082A (ko) 2021-09-15 2024-05-03 하. 룬드벡 아크티에셀스카브 항-cgrp 항체 투약 및 스크리닝 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
AU2015230933B2 (en) * 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
TWI799849B (zh) * 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
CN109952314A (zh) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2020146527A1 (en) * 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Also Published As

Publication number Publication date
KR20220004053A (ko) 2022-01-11
CL2021002866A1 (es) 2022-06-17
AU2020267107A1 (en) 2021-10-07
EP3962522A4 (en) 2023-07-19
BR112020027063A2 (pt) 2021-11-16
ZA202106627B (en) 2025-12-17
CA3133571A1 (en) 2020-11-05
IL287759A (en) 2022-01-01
JP2026016471A (ja) 2026-02-03
GEP20257803B (en) 2025-10-10
EA202192865A1 (ru) 2022-02-14
PH12021552422A1 (en) 2022-07-11
WO2020222892A1 (en) 2020-11-05
GEAP202515803A (en) 2025-06-10
EP3962522A1 (en) 2022-03-09
JOP20210247A1 (ar) 2023-01-30
JP2022533030A (ja) 2022-07-21
US20220251178A1 (en) 2022-08-11
CN113811326A (zh) 2021-12-17
MX2021013426A (es) 2021-12-10
SG11202110637RA (en) 2021-10-28
AU2020267107B2 (en) 2026-04-09
DOP2021000215A (es) 2021-11-21

Similar Documents

Publication Publication Date Title
MA54704A (fr) Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA54709A (fr) Traitement de maux de tête dus à un usage abusif de médicaments à l'aide d'anticorps anti-cgrp ou anti-cgrp-r
EP3471780A4 (en) TREATMENT OF AMD WITH AAV2 VARIANT WITH AFLIBERCEPT
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA52219A (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
EP3414573A4 (en) NOVEL ANTI-LAM AND ANTI-PIM6 / LAM MONOCLONAL ANTIBODIES FOR THE DIAGNOSIS AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
EP3762407A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER WITH ECM AFFINITY PEPTIDES BONDED TO CYTOKINE
EP3645039A4 (en) USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
EP3328429A4 (en) PEPTIDES AND ANTIBODIES FOR THE DISPOSAL OF BIOFILMS
EP3790867A4 (en) KDM1A INHIBITORS FOR DISEASE TREATMENT
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
EP3681508A4 (en) METHOD AND COMPOSITION FOR TREATMENT OF VIRUS INFECTION
EP3863671A4 (en) MONOCLONAL ANTIBODY FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
EP3500278A4 (en) METHOD AND COMPOSITIONS FOR TREATING DISEASES WITH RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS
EP3810091A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION
EP3877418A4 (en) DOSING REGIME OF AN ANTI-TIGIT ANTIBODY FOR THE TREATMENT OF CANCER
EP3902826A4 (en) USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT ATHEROSCLEROSIS
EP3773221A4 (en) TREATMENT OF HYDROCEPHALUS
EP3890722A4 (en) METHODS OF TREATMENT OR PREVENTION OF GOUT OR HYPERURICEMIA
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
MA52590A (fr) Méthodes de traitement de la dépression à l'aide d'anticorps il-23
EP3612214A4 (en) ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA